Larry Dick holds a B.S. in biology from Marquette University and earned aPh.D. in biophysics from The University of Texas at Dallas in the laboratory of Professor Donald Gray. He did postdoctoral research at The University of Texas Southwestern Medical Center with Drs. Clive Slaughter and George DeMartino studying the structure and function of the proteasome. He began his industrial career at MyoGenics/ProScript and was part of the team that discovered the first-in-class proteasome inhibitor VELCADE (bortezomib). For the past 19 years he has worked in Discovery at Millennium/Takeda where he was Director of Biochemistry and a member of the teams that discovered the investigational NEDD8 activating enzyme inhibitor, pevonedistat, the investigational ubiquitin activating enzyme inhibitor, TAK-234, and the proteasome inhibitor NINLARO (ixazomib). Currently he is a Scientific Fellow in the Oncology Clinical Research group working on development of UPS-related investigational drugs.